Is the new bivalent COVID-19 vaccine the booster we’ve been waiting for?

The bivalent COVID-19 vaccine developed by GSK and Sanofi shows promising results with a 64.7% overall effectiveness against symptomatic COVID-19, according to a phase 3 trial. The vaccine performs especially well as a booster, achieving 75.9% efficacy in non-naïve subjects.

Over half of long COVID patients suffer persistent cognitive slowing, new study reveals

Study finds that 53% of long COVID patients experience significant cognitive slowing, a symptom that does not improve over time and is independent of the

January 30, 2024

Forget ‘Pack-Years’ for Lung Cancer Screening Eligibility, Study Suggests

Dropping pack-years for lung cancer screening eligibility in favor of a simpler 20-year history of smoking could substantially increase the number of cancers detected and

April 2, 2024

Common herbicide exposure linked to worse brain function in adolescents

Herbicides are the most used class of pesticides worldwide, with uses in agriculture, homes and industry. Exposures to two of the most popular herbicides were

October 12, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.